Transcatheter treatment of the tricuspid valve: current status and perspectives.
Eur Heart J
; 45(11): 876-894, 2024 Mar 14.
Article
en En
| MEDLINE
| ID: mdl-38426859
ABSTRACT
Transcatheter tricuspid valve interventions (TTVI) are emerging as alternatives to surgery in high-risk patients with isolated or concomitant tricuspid regurgitation. The development of new minimally invasive solutions potentially more adapted to this largely undertreated population of patients, has fuelled the interest for the tricuspid valve. Growing evidence and new concepts have contributed to revise obsolete and misleading perceptions around the right side of the heart. New definitions, classifications, and a better understanding of the disease pathophysiology and phenotypes, as well as their associated patient journeys have profoundly and durably changed the landscape of tricuspid disease. A number of registries and a recent randomized controlled pivotal trial provide preliminary guidance for decision-making. TTVI seem to be very safe and effective in selected patients, although clinical benefits beyond improved quality of life remain to be demonstrated. Even if more efforts are needed, increased disease awareness is gaining momentum in the community and supports the establishment of dedicated expert valve centres. This review is summarizing the achievements in the field and provides perspectives for a less invasive management of a no-more-forgotten disease.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Insuficiencia de la Válvula Tricúspide
/
Implantación de Prótesis de Válvulas Cardíacas
Límite:
Humans
Idioma:
En
Revista:
Eur Heart J
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia